B7H3/IL13Ra2 Bispecific Armored CAR T-Cell Therapy

· Second Affiliated Hospital, School of Medicine, Zhejiang University

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for B7H3/IL13Ra2 Bispecific Armored CAR T-Cell Therapy, covering 2025-11-18 to 2025-11-18. Get the full timeline:

Most recent: Clinical Trial Update: B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma [Phase 1]

See pricing